Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study
Aptahem AB (publ) announces today that the results from the additional analyses performed in cohorts 1 to 4 in the First in Human (FIH) study, have contributed to the clarification of Apta-1’s impact on clinical biomarkers. Next step is to apply for approval to continue the study.
Aptahem has now finalized the analyses recommended by the Data Review Committee. The data showed promising results regarding the effect of Apta-1 on clinical biomarkers. Aptahem will swiftly compile the data and aim to submit to the Ethics Committee and Competent Authority as soon as possible after the data review meeting. The continued clinical program will benefit from these new data and be of great help optimizing the clinical development of Apta-1.
CEO Mikael Lindstam comments:
”Our commitment has always been to the advancement of effective treatments for patients suffering from severe inflammatory conditions. We are very pleased with these findings as they not only validate our pre-clinical studies and theories, but they also provide invaluable insights that will bolster our clinical development path. As we continue to grow our footprint in the realm of potential drug candidates for sepsis and severe inflammatory conditions, these results mark an important milestone.”
The objectives with the phase 1a study is to evaluate the safety and tolerability of Apta-1 in multiple doses.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.